logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
KVAC
Keen Vision Acquisition Corporation Ordinary Shares
12.55
5 x 12.40
1 x 12.99
bid
ask
+
0.15
1.21%
12:05 PM
timesize
Ytd6.81%
1y9.13%
12.10
day range
12.64
11.37
52 week range
12.55
Open12.16Prev Close12.40Low12.10High12.64Mkt Cap112.06M
Vol2.04KAvg Vol1.80KEPS0.18P/E67.40Forward P/EN/A
Beta-0.04Short Ratio0.04Inst. Own66.77%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2850-d Avg12.27200-d Avg11.941yr Est0.00

KVAC News

Financial Comparison: Blaize (NASDAQ:BZAI) and Keen Vision Acquisition (NASDAQ:KVAC)
defenseworld.net
Financial Comparison: Blaize (NASDAQ:BZAI) and Keen Vision Acquisition (NASDAQ:KVAC)

Blaize (NASDAQ: BZAI - Get Free Report) and Keen Vision Acquisition (NASDAQ: KVAC - Get Free Report)

Keen Vision Acquisition (NASDAQ:KVAC) Shares Up 0.9% – Here’s What Happened
defenseworld.net
Keen Vision Acquisition (NASDAQ:KVAC) Shares Up 0.9% – Here’s What Happened

Keen Vision Acquisition Corporation (NASDAQ: KVAC - Get Free Report)'s share price shot up 0.9% on M

65,256 Shares in Keen Vision Acquisition Corporation $KVAC Acquired by Crossingbridge Advisors LLC
defenseworld.net
65,256 Shares in Keen Vision Acquisition Corporation $KVAC Acquired by Crossingbridge Advisors LLC

Crossingbridge Advisors LLC acquired a new stake in Keen Vision Acquisition Corporation (NASDAQ: KVA

Keen Vision Acquisition (NASDAQ:KVAC) Stock Price Up 0.1% – Time to Buy?
defenseworld.net
Keen Vision Acquisition (NASDAQ:KVAC) Stock Price Up 0.1% – Time to Buy?

Keen Vision Acquisition Corporation (NASDAQ: KVAC - Get Free Report)'s share price traded up 0.1% du

Keen Vision Acquisition (NASDAQ:KVAC) Trading 0.5% Higher – Still a Buy?
defenseworld.net
Keen Vision Acquisition (NASDAQ:KVAC) Trading 0.5% Higher – Still a Buy?

Keen Vision Acquisition Corporation (NASDAQ: KVAC - Get Free Report) shares traded up 0.5% during mi

Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
globenewswire.com
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR

BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical

Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
globenewswire.com
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress

BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit
globenewswire.com
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Prese

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutica

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction
globenewswire.com
Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-0

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutica

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
globenewswire.com
Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Fa

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutica

Medera's Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht
globenewswire.com
Medera's Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical

Cutting-Edge Cardiac Research: Novoheart's CTScreen™ system has been installed at UMC Utrecht, equip

Medera, Inc. to Participate in Two Upcoming Investor Conferences
globenewswire.com
Medera, Inc. to Participate in Two Upcoming Investor Conferences

SUMMIT, N.J. and BOSTON, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Medera, Inc., (“Medera”), a clinical-stag

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
prnewswire.com
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Scr

Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failur

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
prnewswire.com
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase

Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing over US$1

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Keen Vision Acquisition Corp. - KVAC
prnewswire.com
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Keen Vision Acquisit

NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"),

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
prnewswire.com
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporati

Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascu

Keen Vision Acquisition Corporation Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing September 15, 2023
prnewswire.com
Keen Vision Acquisition Corporation Announces the Separate Trading of its Ordinary Shares and Warran

SUMMIT, N.J., Sept. 14, 2023 /PRNewswire/ -- Keen Vision Acquisition Corporation ("KVAC") announced